Dow Jones Newswires: WuXi XDC sets its Hong Kong IPO price at high end of range

A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.

Previous post Dow Jones Newswires: Japan’s exports rise in October, helped by car shipments
Next post : Biden touts ‘constructive and productive’ meeting with Xi — and will ‘trust, but verify’